Skip to main content

Table 2 Methotrexate therapy effect on pain intensity according to the McGill pain index and avascular osteonecrosis chronic pain evaluation

From: Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis

Patient no.

McGill pain index reductiona

Avascular osteonecrosis pain reductionb

Composite effectc

Responder

 14

Yes (11.8%)

N/A

Yes

 10

Yes (18.2%)

N/A

Yes

 11

Yes (20.0%)

N/A

Yes

 12

Yes (36.8%)

N/A

Yes

 13

Yes (31.4%)

N/A

Yes

 8

Yes (75.7%)

Yes (≥50%)

Yes

 1

Yes (24.5%)

Yes (≥50%)

Yes

 3

Yes (34.8%)

Yes (≥50%)

Yes

 4

No (−19.5%)

Yes (≥50%)

Yes

 9

No (−2.4%)

Yes (≥50%)

Yes

Nonresponder

 6

No (−25.6%)

No

No

 7

No (−9.6%)

No

No

 2

No (−29.7%)

N/A

No

 5

No (−2.6%)

N/A

No

  1. N/A not applicable
  2. aNegative values indicate increase of the index
  3. bAvascular osteonecrosis pain as defined in Fig. 1d
  4. cComposite effect means either avascular osteonecrosis pain reduction or lower McGill pain index or both